Dapagliflozin

Dapagliflozin (5 mg, 10 mg) is a pioneer selective sodium-glucose co-transporter 2 (SGLT2) inhibitor on the WHO Model List of Essential Medicines. It acts in the S1 segment of the renal proximal tubule, blocking glucose and sodium reabsorption and promoting the urinary excretion of 70 to 80 grams of glucose per day. In addition to glycemic reduction, it induces osmotic diuresis, decreases intraglomerular pressure, reduces cardiac preload and afterload, and confers landmark cardio-renal protection. Indicated for type 2 diabetes mellitus, heart failure with reduced or preserved ejection fraction (HFrEF/HFpEF), and chronic kidney disease (CKD) to slow renal decline.

Metformin Hydrochloride and Dapagliflozin unites a biguanide with an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor on the WHO Model List of Essential Medicines. Metformin reduces hepatic glucose production and enhances insulin sensitivity, while dapagliflozin acts insulin-independently in the proximal renal tubules to block glucose reabsorption, promoting the urinary excretion of approximately 70-80 grams of glucose per day (equating to 280-320 kcal/day), producing glycemic control, modest weight loss, and blood pressure reduction. Indicated for type 2 diabetes mellitus, with proven cardiorenal benefits.

Metformin Hydrochloride and Dapagliflozin unites a biguanide with an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor on the WHO Model List of Essential Medicines. Metformin reduces hepatic glucose production and enhances insulin sensitivity, while dapagliflozin acts insulin-independently in the proximal renal tubules to block glucose reabsorption, promoting the urinary excretion of approximately 70-80 grams of glucose per day (equating to 280-320 kcal/day), producing glycemic control, modest weight loss, and blood pressure reduction. Indicated for type 2 diabetes mellitus, with proven cardiorenal benefits.

Dapagliflozin (5 mg, 10 mg) is a pioneer selective sodium-glucose co-transporter 2 (SGLT2) inhibitor on the WHO Model List of Essential Medicines. It acts in the S1 segment of the renal proximal tubule, blocking glucose and sodium reabsorption and promoting the urinary excretion of 70 to 80 grams of glucose per day. In addition to glycemic reduction, it induces osmotic diuresis, decreases intraglomerular pressure, reduces cardiac preload and afterload, and confers landmark cardio-renal protection. Indicated for type 2 diabetes mellitus, heart failure with reduced or preserved ejection fraction (HFrEF/HFpEF), and chronic kidney disease (CKD) to slow renal decline.

Sitagliptin Phosphate (50 mg, 100 mg) is an orally active, highly selective beta-amino acid-derived dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It competitive inhibits DPP-4, preventing the rapid enzymatic degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), prolonging postprandial active incretin levels. This stimulates glucose-dependent insulin secretion and suppresses postprandial glucagon secretion without causing hypoglycemia or weight gain. Indicated for type 2 diabetes mellitus as monotherapy or combination therapy.

Sitagliptin Phosphate (50 mg, 100 mg) is an orally active, highly selective beta-amino acid-derived dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It competitive inhibits DPP-4, preventing the rapid enzymatic degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), prolonging postprandial active incretin levels. This stimulates glucose-dependent insulin secretion and suppresses postprandial glucagon secretion without causing hypoglycemia or weight gain. Indicated for type 2 diabetes mellitus as monotherapy or combination therapy.

Vildagliptin (50 mg, 100 mg SR) is a cyanopyrrolidine dipeptidyl peptidase-4 (DPP-4) inhibitor. It binds covalently to the catalytic site of DPP-4 with slow substrate-like kinetics, slowing enzyme dissociation and providing sustained incretin (GLP-1 and GIP) stabilization. This increases insulin secretion and suppresses inappropriate glucagon secretion in a glucose-dependent manner, eliminating intrinsic hypoglycemia risk. Indicated for the treatment of type 2 diabetes mellitus.

Vildagliptin (50 mg, 100 mg SR) is a cyanopyrrolidine dipeptidyl peptidase-4 (DPP-4) inhibitor. It binds covalently to the catalytic site of DPP-4 with slow substrate-like kinetics, slowing enzyme dissociation and providing sustained incretin (GLP-1 and GIP) stabilization. This increases insulin secretion and suppresses inappropriate glucagon secretion in a glucose-dependent manner, eliminating intrinsic hypoglycemia risk. Indicated for the treatment of type 2 diabetes mellitus.

Teneligliptin (20 mg) is a third-generation, highly selective, orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. It features a unique J-shaped conformation that binds to subsite S1, S2, and S2-extensive pockets of the DPP-4 enzyme, achieving powerful enzyme inhibition (>80% at 24 hours) with a half-life of 24.2 hours. It is eliminated through dual hepatic and renal pathways, allowing standard once-daily dosing across all stages of chronic kidney disease (CKD) without dose adjustments. Indicated for type 2 diabetes mellitus as monotherapy or in combination with other oral antidiabetic agents.

Teneligliptin (20 mg) is a third-generation, highly selective, orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. It features a unique J-shaped conformation that binds to subsite S1, S2, and S2-extensive pockets of the DPP-4 enzyme, achieving powerful enzyme inhibition (>80% at 24 hours) with a half-life of 24.2 hours. It is eliminated through dual hepatic and renal pathways, allowing standard once-daily dosing across all stages of chronic kidney disease (CKD) without dose adjustments. Indicated for type 2 diabetes mellitus as monotherapy or in combination with other oral antidiabetic agents.

Metformin Hydrochloride and Dapagliflozin unites a biguanide with an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor on the WHO Model List of Essential Medicines. Metformin reduces hepatic glucose production and enhances insulin sensitivity, while dapagliflozin acts insulin-independently in the proximal renal tubules to block glucose reabsorption, promoting the urinary excretion of approximately 70-80 grams of glucose per day (equating to 280-320 kcal/day), producing glycemic control, modest weight loss, and blood pressure reduction. Indicated for type 2 diabetes mellitus, with proven cardiorenal benefits.

Sitagliptin Phosphate (50 mg, 100 mg) is an orally active, highly selective beta-amino acid-derived dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It competitive inhibits DPP-4, preventing the rapid enzymatic degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), prolonging postprandial active incretin levels. This stimulates glucose-dependent insulin secretion and suppresses postprandial glucagon secretion without causing hypoglycemia or weight gain. Indicated for type 2 diabetes mellitus as monotherapy or combination therapy.

Metformin Hydrochloride and Sitagliptin is a landmark incretin-based dual antidiabetic combination on the WHO Model List of Essential Medicines. Sitagliptin selectively inhibits DPP-4, elevating active GLP-1 and GIP to enhance glucose-dependent insulin synthesis and suppress postprandial glucagon, while metformin addresses insulin resistance and decreases hepatic glucose production. Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Metformin Hydrochloride and Sitagliptin is a landmark incretin-based dual antidiabetic combination on the WHO Model List of Essential Medicines. Sitagliptin selectively inhibits DPP-4, elevating active GLP-1 and GIP to enhance glucose-dependent insulin synthesis and suppress postprandial glucagon, while metformin addresses insulin resistance and decreases hepatic glucose production. Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Metformin Hydrochloride and Dapagliflozin unites a biguanide with an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor on the WHO Model List of Essential Medicines. Metformin reduces hepatic glucose production and enhances insulin sensitivity, while dapagliflozin acts insulin-independently in the proximal renal tubules to block glucose reabsorption, promoting the urinary excretion of approximately 70-80 grams of glucose per day (equating to 280-320 kcal/day), producing glycemic control, modest weight loss, and blood pressure reduction. Indicated for type 2 diabetes mellitus, with proven cardiorenal benefits.

Sitagliptin Phosphate (50 mg, 100 mg) is an orally active, highly selective beta-amino acid-derived dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It competitive inhibits DPP-4, preventing the rapid enzymatic degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), prolonging postprandial active incretin levels. This stimulates glucose-dependent insulin secretion and suppresses postprandial glucagon secretion without causing hypoglycemia or weight gain. Indicated for type 2 diabetes mellitus as monotherapy or combination therapy.

Linagliptin (5 mg) is a xanthine-based dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It binds tightly and pseudo-irreversibly to DPP-4 with 8-fold higher potency than other gliptins. Unlike other DPP-4 inhibitors, it is excreted predominantly unchanged via the enterohepatic bile system (95%) with less than 5% renal excretion. Consequently, it requires NO dose adjustments in patients with any degree of renal impairment or hepatic dysfunction, making it the DPP-4 inhibitor of choice in chronic kidney disease. Indicated for type 2 diabetes mellitus.

Linagliptin (5 mg) is a xanthine-based dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It binds tightly and pseudo-irreversibly to DPP-4 with 8-fold higher potency than other gliptins. Unlike other DPP-4 inhibitors, it is excreted predominantly unchanged via the enterohepatic bile system (95%) with less than 5% renal excretion. Consequently, it requires NO dose adjustments in patients with any degree of renal impairment or hepatic dysfunction, making it the DPP-4 inhibitor of choice in chronic kidney disease. Indicated for type 2 diabetes mellitus.

Linagliptin (5 mg) is a xanthine-based dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It binds tightly and pseudo-irreversibly to DPP-4 with 8-fold higher potency than other gliptins. Unlike other DPP-4 inhibitors, it is excreted predominantly unchanged via the enterohepatic bile system (95%) with less than 5% renal excretion. Consequently, it requires NO dose adjustments in patients with any degree of renal impairment or hepatic dysfunction, making it the DPP-4 inhibitor of choice in chronic kidney disease. Indicated for type 2 diabetes mellitus.

Linagliptin (5 mg) is a xanthine-based dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It binds tightly and pseudo-irreversibly to DPP-4 with 8-fold higher potency than other gliptins. Unlike other DPP-4 inhibitors, it is excreted predominantly unchanged via the enterohepatic bile system (95%) with less than 5% renal excretion. Consequently, it requires NO dose adjustments in patients with any degree of renal impairment or hepatic dysfunction, making it the DPP-4 inhibitor of choice in chronic kidney disease. Indicated for type 2 diabetes mellitus.

Metformin Hydrochloride and Vildagliptin is a weight-neutral, low-hypoglycemia dual antidiabetic formulation. Metformin decreases hepatic gluconeogenesis and intestinal glucose absorption, while vildagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor, prevents the enzymatic degradation of endogenous incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin secretion and suppressing inappropriate glucagon secretion by alpha cells. Indicated for the management of type 2 diabetes mellitus inadequately controlled by metformin monotherapy.

Metformin Hydrochloride and Vildagliptin is a weight-neutral, low-hypoglycemia dual antidiabetic formulation. Metformin decreases hepatic gluconeogenesis and intestinal glucose absorption, while vildagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor, prevents the enzymatic degradation of endogenous incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin secretion and suppressing inappropriate glucagon secretion by alpha cells. Indicated for the management of type 2 diabetes mellitus inadequately controlled by metformin monotherapy.

Metformin Hydrochloride and Teneligliptin combines an insulin sensitizer with a long-acting peptidomimetic DPP-4 inhibitor. Teneligliptin possesses a unique "J-shaped" chemical structure with five consecutive binding anchors on the DPP-4 enzyme, providing potent and prolonged (>24 hour) incretin stabilization without requiring dose reduction in renal impairment, while metformin controls fasting hyperglycemia. Indicated for type 2 diabetes mellitus in adult patients.

Metformin Hydrochloride and Teneligliptin combines an insulin sensitizer with a long-acting peptidomimetic DPP-4 inhibitor. Teneligliptin possesses a unique "J-shaped" chemical structure with five consecutive binding anchors on the DPP-4 enzyme, providing potent and prolonged (>24 hour) incretin stabilization without requiring dose reduction in renal impairment, while metformin controls fasting hyperglycemia. Indicated for type 2 diabetes mellitus in adult patients.

Vildagliptin (50 mg, 100 mg SR) is a cyanopyrrolidine dipeptidyl peptidase-4 (DPP-4) inhibitor. It binds covalently to the catalytic site of DPP-4 with slow substrate-like kinetics, slowing enzyme dissociation and providing sustained incretin (GLP-1 and GIP) stabilization. This increases insulin secretion and suppresses inappropriate glucagon secretion in a glucose-dependent manner, eliminating intrinsic hypoglycemia risk. Indicated for the treatment of type 2 diabetes mellitus.